• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Holmusk and Veradigm Reach New Data Enrichment Milestone in Strategic Collaboration

    7/24/24 8:00:00 AM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email

    Veradigm Network EHR data enables a deeper understanding of the patient journey and disorder progression

    NEW YORK and CHICAGO, July 24, 2024 /PRNewswire/ -- Holmusk, a leading global mental health real-world evidence company, and Veradigm® (OTC:MDRX), a leading healthcare data and technology solutions provider, today announced that they have reached a new data enrichment milestone in their strategic collaboration. This collaboration, announced last year, draws upon the strengths of each company to drive innovation and generate real-world evidence designed to accelerate mental health research and care. Veradigm also led Holmusk's 2023 Series B funding round as part of this collaboration.

    To reach this milestone, Holmusk and Veradigm collaborated to identify additional insights to assess disorder progression within Veradigm Network EHR data, enriching millions of patient profiles with sufficient data points for inclusion in real-world data investigations. Holmusk worked with Veradigm's Medical Informatics team to transform semi-structured data captured at the point-of-care into analyzable, structured data. This information provides key insights into how a patient's disorder evolves throughout the clinical care journey. A high density of psychometric scales enables leaders in research, government, healthcare, and academia to more granularly assess treatment effectiveness, care patterns and gaps, and disorder progression.

    "As a psychiatrist, investigator, and professor, access to outcome-rich data like these is invaluable when conducting research on the identification, characterization, and treatment of those with severe psychiatric disorders. This milestone marks a turning point in our expertise and ability to harness outcome measures at scale and at a level of granularity that is all too often missing from real-word data." - Dr. Christoph Correll, Professor of Psychiatry, Zucker School of Medicine, Hofstra/Northwell; Professor and Chair, Department of Child and Adolescent Psychiatry, Charité University Medicine; Scientific Advisor, Holmusk

    These patient-level data are now available in NeuroBlu Data, the largest NLP-enriched real-world dataset for mental health. Holmusk continues to deepen the dataset's value as the leading global source for mental health insights from clinical care through strategic partnerships.

    "Holmusk's collaboration with Veradigm is based on our shared vision to transform evidence generation for research and clinical practice with real-world data. This milestone has uncovered a significant volume of measures of mental health progression, enriching NeuroBlu Data and the ability to deliver precision neuroscience. We are continuing to build upon this unparalleled source of rich, real-world data to address the evidence gap in mental health and positively impact patient outcomes." - Nawal Roy, Founder & CEO of Holmusk

    "By combining Holmusk's global leadership in clinical insights for mental health with Veradigm's direct access, network reach, and technical expertise for enhancing EHR-derived data, we have uncovered these underutilized data points, enhancing the understanding of treatment strategies for mental health conditions. Together, we've tapped into a wealth of data that is key to advancing patient care in mental health." - Tom Langan, Interim CEO, Veradigm

    Through this strategic collaboration, Holmusk and Veradigm will continue to leverage their collective expertise to optimize data availability and standardization to support robust real-world evidence generation for mental health.

    About Holmusk: Holmusk is on a mission to harness real-world data to transform research and behavioral health care. Combining leading behavioral health data with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusk is headquartered in New York, with four additional offices worldwide. For more information, please visit www.holmusk.com.

    About Veradigm: Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

    Cision View original content:https://www.prnewswire.com/news-releases/holmusk-and-veradigm-reach-new-data-enrichment-milestone-in-strategic-collaboration-302203088.html

    SOURCE Holmusk

    Get the next $MDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey Solution

    Veradigm (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into real‑world evidence generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm's FollowMyHealth patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project‑specific invitations through trusted channels within FollowMyHealt

    2/13/26 8:01:00 AM ET
    $MDRX
    EDP Services
    Technology

    Veradigm to Release Business Update February 17th and Host Investor Call February 18th

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, February 17, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm invest

    2/10/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan to December 31, 2026 (the "Rights Plan"). The Board's decision to extend the Rights Plan is based on its determination that many of the underlying risks and conditions that existed upon the initial adoption of the Rights Plan will continue to be present beyond February 20, 2026. Accordingly, the Rights Plan is being extended to continue to ensure that all Veradigm stockholders have the opportunity to realize the full potential value of their in

    2/2/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    SEC Filings

    View All

    Veradigm Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Veradigm Inc. (0001124804) (Filer)

    2/17/26 4:10:26 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Veradigm Inc.

    SCHEDULE 13G/A - Veradigm Inc. (0001124804) (Subject)

    2/13/26 1:08:01 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form 8-A12G/A filed by Veradigm Inc.

    8-A12G/A - Veradigm Inc. (0001124804) (Filer)

    2/2/26 4:47:45 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Veradigm downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

    3/19/24 7:50:39 AM ET
    $MDRX
    EDP Services
    Technology

    Barclays initiated coverage on Veradigm with a new price target

    Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

    1/3/24 8:00:02 AM ET
    $MDRX
    EDP Services
    Technology

    Veradigm downgraded by Argus

    Argus downgraded Veradigm from Buy to Hold

    7/6/23 9:00:49 AM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer

    Healthcare IT Veteran - former AWS and Cerner senior executive - to lead and accelerate innovation across Veradigm's unique footprint Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today appoints Tehsin Syed, a healthcare technology leader with over two decades of experience, as Chief Product and Technology Officer. Syed most recently served as General Manager, AWS Health AI (Amazon Web Services). Under his leadership, the organization scaled as a growth engine, with net-new products for ambient clinical documentation, genomics, and medical imaging, and interoperability elevated to enterprise grade - capabilities trusted by providers, payers, bioph

    11/3/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    $MDRX
    Financials

    Live finance-specific insights

    View All

    Veradigm to Release Business Update February 17th and Host Investor Call February 18th

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, February 17, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm invest

    2/10/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Amends and Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan for an additional six months (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire at 5:00PM New York City time on August 20, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to February 20, 2026. In addition, the amendment to the Rights Plan changes the triggering threshold such that the rights would become exercisable only if a person or group acquires bene

    8/20/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm to Release Business Update June 23rd and Host Investor Call June 24th

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participan

    6/18/25 5:27:00 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/8/24 10:29:29 AM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & Chief HR Officer Hammond Lisa was granted 58,140 shares, increasing direct ownership by 50% to 174,175 units (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/5/25 5:28:24 PM ET
    $MDRX
    EDP Services
    Technology

    SVP General Counsel Vakharia Tejal was granted 69,768 shares, increasing direct ownership by 22% to 387,476 units (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/5/25 5:22:40 PM ET
    $MDRX
    EDP Services
    Technology

    Director Sacks Jonathan S was granted 46,512 shares and converted options into 8,696 shares (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    6/3/25 9:28:21 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

    4/A - Veradigm Inc. (0001124804) (Issuer)

    3/15/24 5:16:45 PM ET
    $MDRX
    EDP Services
    Technology

    Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

    4 - Veradigm Inc. (0001124804) (Issuer)

    3/4/24 9:50:46 PM ET
    $MDRX
    EDP Services
    Technology